(Q39245623)

English

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro (English)

1 reference

Europe PubMed Central

10 September 2017

apoptotic process

0 references

allosteric inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

carcinoid tumor

1 reference

based on heuristic

inferred from title

author name string

Yash Somnay

1

1 reference

Europe PubMed Central

10 September 2017

Kevin Simon

2

1 reference

Europe PubMed Central

10 September 2017

April D Harrison

3

1 reference

Europe PubMed Central

10 September 2017

Selvi Kunnimalaiyaan

4

1 reference

Europe PubMed Central

10 September 2017

Herbert Chen

5

1 reference

Europe PubMed Central

10 September 2017

Muthusamy Kunnimalaiyaan

6

1 reference

Europe PubMed Central

10 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2013

1 reference

Europe PubMed Central

10 September 2017

Anti-Cancer Drugs

1 reference

Europe PubMed Central

10 September 2017

24

1 reference

Europe PubMed Central

10 September 2017

1

1 reference

Europe PubMed Central

10 September 2017

66-72

1 reference

Europe PubMed Central

10 September 2017

The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Translation of molecular pathways into clinical trials of neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Targeting PI3 kinase/AKT/mTOR signaling in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Targeting the PI3K signaling pathway in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

AKT and PTEN expression in human gastrointestinal carcinoid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Treatment of advanced carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

10 September 2017

Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

14 September 2017

Elevated XIAP expression alone does not confer chemoresistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

25 September 2017

Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

17 June 2018

Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

21 August 2018

Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

21 August 2018

Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

21 August 2018

Novel survivin-related members of the inhibitor of apoptosis (IAP) family.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3510354

21 August 2018

Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147412

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147412

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147412

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy of neuroendocrine cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23147412

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/CAD.0B013E3283584F75

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39245623&oldid=1815861054"